Opko Health, Inc. · NASDAQ:OPK
Opko Health — Shareholder Meeting (June 2011)
23 slides from Opko Health's shareholder meeting presentation, Jun 10, 2011
Slide 1: Annual Stockholders Meeting June 9, 2011
Annual Stockholders Meeting June 9, 2011
Slide 2: Cautionary Statement
Cautionary Statement This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "sho
Slide 3: Management Team
Management Team Phillip Frost, M.D. Chairman and CEO TEVA (Chairman), IVAX (Chairman and CEO), Key Pharmaceuticals (Chairman) Jane H. Hsiao, Ph.D. Vice Chairman and Chief Technology Officer IVAX (Chief Technology Officer) Steven Rubin Executive Vice President and Chief Administrative Officer IVAX (G
Slide 4: Company Overview
Company Overview Discovery Earlier Clinical Commercial Mid / Late Clinical • Opportunistic pharmaceutical and diagnostics company • Focused on large, high growth markets • Experience in development and commercialization. Multiple game-changing opportunities New molecular diagnostics platform targeti
Slide 5: Molecular Diagnostics
Molecular Diagnostics Innovative platform technology for the discovery of disease-specific antibodies Initially targeting diseases for which there is no definitive blood test Simple tests for Alzheimer's Disease, multiple forms of cancer and other conditions Non-exclusive collaboration with BMS for
Slide 6: Antibody Background
The immune response amplifies antibodies that recognize disease-specific molecules (antigens) Antibody Background 6 Foreign Antigen Y Amplification Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y B Cells Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Antibodies (100s o
Slide 7: Technology Overview
Technology Overview 7 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y + Y Y Identifies synthetic compounds that act as "antigen surrogates" Capture Agent Microarray Spot Proprietary Antibody Capture Technology Discovery of Autoantibody-Ligand Pairs ••••••••••••••••••• ••••••••••••••••••• •••••••••••
Slide 8: Simple Blood Tests: Discovery of Specific Antibodies For Cancer Diagnosis
8 Four peptoids found to distinguish NSCLC patients in an initial study Four peptoids found to distinguish Stage I pancreatic cancer patients in an initial study Simple Blood Tests Discovery of Specific Antibodies For Cancer Diagnosis
Slide 9: Alzheimer's Disease
Lupus Parkinson's Healthy, Non-Demented Alzheimer's Three molecules identified that distinguish Alzheimer's patients from age-matched controls ADP1 and ADP3 bind antibodies distinct from those bound by ADP2, i.e., two AD-specific autoantibodies have been discovered 9 Alzheimer's Disease
Slide 10: Alzheimer's Disease - Further Validation
Alzheimer's Disease - Further Validation Conducting 580 patient sample validation study 200 AD, 200 matched controls, 180 other diseases Final results expected by late 2011 10 Ongoing validation study with positive initial results (140 samples) ADP1 Intensity ADP2 ADP3 Intensity Intensity
Slide 11: Potential for Early Diagnosis in MCI Patients
11 1 2 3 4 5 6 7 8 9 10 11 12 13 AD NC LBD LewyBody Dementia Patients Intensity (X103) Potential for Early Diagnosis in MCI Patients ADP3 Microarray
Slide 12: Second Generation Discovery Platform
Second Generation Discovery Platform 12 AD: 150 AD: 72 Competition Assays AD: At least 9 Antibodies
Slide 13: A Commercial Test for Alzheimer's
A Commercial Test for Alzheimer's 13 Y Y HRP Colorless substrate Blue Product Serum Dilution Intensity AD Intensity Serum Dilution Normal B. ELISA Plate
Slide 14: ELISA Study of Plasma Samples: Agreement With Clinical Diagnosis
ELISA Study of 106 Plasma Samples: Agreement With Clinical Diagnosis 14 Intensity AD Demented Non-Demented Non-AD Severe Depression Lewy Body Dementia
Slide 15: Summary of Diagnostic Work
Summary of Diagnostic Work A highly reliable, commercially viable blood test for Alzheimer's disease is in hand. Test can distinguish between AD and certain other dementias. Preliminary results indicate high sensitivity for early stage Alzheimer's disease (MCI stage). R&D will be completed late summ
Slide 16: Potential for Therapeutic Applications
Potential for Therapeutic Applications 16 Compound Library Therapeutic proof of concept demonstrated Initial proof of concept demonstrated in Pemphigus Vulgaris, an autoimmune skin blistering disease Approach: Screen for "desmoglein surrogates" that bind to the offending antibody and prevent it from
Slide 17: CURNA - Natural Antisense Transcript Inhibitors
CURNA - Natural Antisense Transcript Inhibitors 17 Novel technology utilizes short, single-strand oligonucleotide Up-regulation of protein production through interference with non-coding RNA's (natural antisense) >80 protein targets across broad therapeutic spectrum were up-regulated in vitro Geneti
Slide 18: Protein Vaccine Platform
Protein Vaccine Platform Limitations of current influenza vaccines Inability to respond to mutations ? inadequate protection Inefficient seasonal development and production timelines Minimally glycosylated protein vaccine provides broad protection against various viral strains Recombinant protein en
Slide 19: Respiratory Therapeutics
Respiratory Therapeutics 19 OPK-0018: Lead Compound for Asthma & COPD Novel heparin-derived sulfated disaccharide Novel mechanism of action No anti-coagulant effects Human feasibility study for asthma successfully completed Anti-inflammatory and anti-allergic efficacy in animal models Effective oral
Slide 20: Rolapitant - Phase III (out-licensed)
Rolapitant - Phase III (out-licensed) 20 Potential best-in-class compound for CINV NK-1 Receptor Antagonist for CINV and PONV Acquired from Schering-Plough and out-licensed to TESARO Up to $121mm milestones plus tiered double-digit royalties Global emesis market estimated at $2B+ in 2009 Positive Ph
Slide 21: OPKO Emerging Markets
OPKO Emerging Markets 21 OPKO Chile - Pharma Genexx, S.A. Fast growing market; approximate10% growth rate in 2010 Rapidly growing sales from >100 products Multiple therapeutic areas including CV, antibiotics, GI and hormones Revenues: $18MM in 2010 and $ 5.8 MM Q1 2011 OPKO Mexico - Pharmacos Exakta
Slide 22: Strategic Investments
Strategic Investments 22 CoCrystal Discovery, Inc. (~16% equity interest*) Founded by Nobel Laureate, Roger Kornberg, Ph.D. New approach to develop broad spectrum anti-viral drugs Sorrento Therapeutics (~23% equity interest*) New technology to produce human monoclonal antibodies libraries that are m
Slide 23: Advisory Board
Advisory Board Richard Lerner, M.D. President of The Scripps Research Institute Tom Kodadek, Ph.D. Professor of Chemistry, The Scripps Research Institute Pascal Goldschmidt, M.D. Dean, University of Miami School of Medicine Tahir Ahmed, M.D. Professor of Pulmonary Medicine, University of Miami Schoo